New Genes in the Carcinogenesis of Colorectal Cancer

Assiut University

Status: Unknown

Conditions: Colo-rectal Cancer

Treatments: Diagnostic Test: blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT03261752

CRC

Details and patient eligibility

About

Colo rectal cancer is one of the greatest ,mutual malignancies worldwide ,accounting for an estimated 1.3 million new cases and >500,000 mortality ⁄ year . is the fourth leading cause of cancer-associated mortality worldwide with speedily ,cumulative ,occurrence rate in the worldwide

Full description

colo rectal cancer represents a global and local problem, as it is one of the commonest types of cancer all over the world. Globally, Colo rectal cancer in women (9.2% of diagnoses) it is the second most common cause of cancer . it is the third most common in men (10.0%). After lung, stomach, and liver cancer it is the fourth most common cause of cancer death.

Cancer is a multistep procedure resulting from an ongoing accretion of genetic and epigenetic fluctuations to the genome.

Spartin is a protein that in humans is encoded by the SPG20 gene. This protein may be involved in endosomal trafficking, microtubule dynamics, or both functions. Aberrant promoter methylation of genes is a common epigenetic alteration in colo rectal cancer .

This has stimulated the prospect to implement a dependable, reasonable and simple approach for Colo rectal detection . The SPG20 gene is situated in chromosome band 13q13.3; the SPG20 gene converts the spartin protein, which is a multi functional protein that has formerly been recognized to be complicated in intra cellular epidermal growth factor receptor trading , The serine-threonine kinase 31 (STK31) gene was initially identified through cDNA subtraction as a testis-specific protein kinase gene expressed in mouse spermatogonia . Recently, STK31 has been described as a novel cancer testis (CT) antigen, highly expressed in Gastrointestinal cancer cells (colo rectal, gastric and esophageal cancer), while restricted to testis and fetal brain in normal tissues .

It was found that SPG20 is mutated in Troy er syndrome, an hereditary spastic paraplegia

Enrollment: 62 estimated patients

Sex: All

Ages: 35 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age between 35-65
• patient with colorectal cancer (at any stage)
• both sex included

Exclusion criteria

• pediatric patients
• patient with insufficient data
• cardiac patient
• pregnant women

Trial design

62 participants in 2 patient groups

patient with cancer

Description:

blood sample will be collected from patient before and after treatment (surgery or chemotherapy)

Treatment:

Diagnostic Test: blood sample

healthy people

Description:

blood sample will be collected for comparison

Treatment:

Diagnostic Test: blood sample